The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and one or more additional asthma controllers).
http://ift.tt/2kjxTeI
Τετάρτη 25 Ιανουαρίου 2017
Mepolizumab (Nucala) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου